Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, focused on developing innovative treatments for central nervous system (CNS) diseases. Established in 2004, the company is primarily working on its lead product candidate, d-Methadone, which is undergoing Phase II clinical trials for conditions such as major depressive disorder and neuropathic pain. In addition to d-Methadone, Relmada is developing LevoCap ER, a sustained-release formulation of levorphanol designed to be abuse-resistant; BuTab, an oral formulation of buprenorphine; and MepiGel, a topical formulation of mepivacaine intended for localized anesthesia. The company's research aims to address significant unmet medical needs in CNS disorders and improve patient outcomes.